Sanofi SA's Fiscal Year is From January To December - All Figures are in EUR, Millions.
The item "Stock-Based-Compensation" stands at 173.00 Million Euros for the trailing twelve months (TTM) period ending 03/31/2025, the lowest value since 12/31/2016.'
Regarding the One-Year-Change of the series, the current value constitutes a decrease of -60.95 percent compared to the value the year prior.
The 1 year change in percent is -60.95.
The 3 year change in percent is -54.23.
The 5 year change in percent is -54.83.
The 10 year change in percent is 103.53.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Stock Based Compensation | 905,699,262,464.00 |
![]() | Johnson & Johnson - Stock Based Compensation | 486,508,953,600.00 |
![]() | AbbVie Inc - Stock Based Compensation | 399,570,305,024.00 |
![]() | Roche Holding AG - Stock Based Compensation | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Stock Based Compensation | 280,205,508,085.11 |